Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients
This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay relapses in patients with glioblastoma compared to the standard care consisting in observation with brain MRI every 3 months and rechallenging with TMZ at relapse (Stop and Go arm).
Glioblastoma
DRUG: Temozolomide|DRUG: Temozolomide
to determine whether prolonged administration of Temozolomide in glioblastoma patients increase their progression-free and overall survival at 6 months, 36 months
safety and adverse event profile of prolonged adjuvant Temozolomide, 3 years
This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay relapses in patients with glioblastoma compared to the standard care consisting in observation with brain MRI every 3 months and rechallenging with TMZ at relapse (Stop and Go arm).